Сравнительная оценка влияния сочетанного применения препаратов Фелиферон и Азоксивет и препарата Глобфел-4 при ринотрахеите кошек на гематологические показатели белой крови

The comparative effect of the combined drugs Feliferon and Azoksivet and the drug Globfel-4 for rhinotracheitis in felines on hematological parameters of white blood was studied. In our study on the treatment of viral rhinotracheitis, 16 cats were examined. During the experiment, all cats showed the following clinical signs: lethargy, fever, leakage from the eyes and nasal passages. The animals were kept in separate cages in accordance with the European Convention for the Protection of Vertebrates. The control group was given 1 ml subcutaneously, once a day every other day, with a course of 7 injections, immunoglobulin against rhinotracheitis, calicivirus and chlamydia - Globfel-4. The experimental group was treated with drugs Azoxivet intramuscularly in a course of 7 injections, once a day every other day, and Feliferon at a dose of 400,000 IU intramuscularly, once a day. The course of treatment was 7 days. Blood sampling was performed from the anterior saphenous vein of the forearm before and after therapy. The concentration of erythrocytes and hemoglobin was determined on an automatic hematology analyzer Mindray BC-2800. When treating cats with rhinotracheitis with Globfel-4, pronounced leukocytosis, absolute and relative lymphocytosis were noted. With the combined use of Azoxivet and Feliferon, these blood changes do not occur. When treating cats with rhinotracheitis with Globfel-4 or the combined use of Azoxivet and Feliferon, the absolute concentrations of monocytes and granulocytes increase within the physiological norm. The relative concentrations of these white blood phrases increase within the physiological norm only with the combined use of Azoxivet and Feliferon.Изучалось сравнительное влияние сочетанного препаратов Фелиферон и Азоксивет и препарата Глобфел-4 при ринотрахеите кошек на гематологические показатели белой крови. В нашем исследовании по изучению методов лечения вирусного ринотрахеита было обследовано 16 кошек. У всех кошек в период проведения опыта выявлены следующие клинические признаки: вялость, повышение температуры, истечение из глаз и носовых путей. Животные содержались в отдельных клетках в соответствии с Европейской конвенцией по защите позвоночных. Контрольной группе поставили подкожно по 1 мл, 1 раз в сутки через день, курсом 7 введений, иммуноглобулин против ринотрахеита, калицивироза и хламидиоза – Глобфел-4. Опытную группу лечили препаратами Азоксивет – внутримышечно курсом 7 введений, 1 раз в сутки через день, и Фелиферон в дозе 400 000 МЕ внутримышечно, 1 раз в день, курс лечения 7 дней. Забор крови проводили из передней подкожной вены предплечья до начала терапии и после. Концентрацию эритроцитов и гемоглобина определяли на гематологическом автоматическом анализаторе Mindray BC-2800. При терапии кошек с ринотрахеитом препаратом Глобфел-4 отмечается выраженный лейкоцитоз, абсолютный и относительный лимфоцитоз. При сочетанном применении Азоксивета и Фелиферона данных изменений крови не происходит. При терапии кошек с ринотрахеитом препаратом Глобфел-4 или сочетанным применением препаратов Азоксивет и Фелиферон повышаются в пределах физиологической нормы абсолютные концентрации моноцитов и гранулоцитов. Относительные концентрации этих фраций белой крови возрастают в пределах физиологической нормы только при сочетанном применении препаратов Азоксивет и Фелиферон

Influence of long-term antibiotic therapy on gut microbiome composition and metabolic profile in pulmonary tuberculosis

The use of long-term multicomponent antibiotic therapy is the most effective way to treat tuberculosis (TB). However, little is known about the effect of this chemotherapy on the human intestinal microflora. The purpose of this study was to analyze an effect of long-term antibiotic therapy on gut microbiome composition and metabolic profile in TB patients. We used deep sequencing of fecal samples from 23 treatment-naive TB patients to reconstruct the metabolic capacity and strain/species-level abundance in the gut microbiome. Two fecal samples were obtained from each patient: before and after treatment. We showed that TB treatment regimen does not disrupt the overall diversity of the gut microbiome but does have an impact on gut bacterial microbiome composition and metabolic profile. While taking first-line anti-tuberculosis drugs (isoniazid, rifampicin, ethambutol, pyrazinamide), TB patients showed an apparent increase in Actinobacteria abundance. Pairwise comparison of metagenomic data revealed 28 differentially represented bacterial taxa, of which three species Bacteroides cellulosilyticus, Enterocloster aldensis, Clostridium spiroforme were strongly enriched in TB patients post-chemotherapy, whereas 25 species were enriched in TB patients before treatment (Bifidobacterium catenulatum, Enterococcus faecium, Bacteroides salyersiae, Bacteroides xylanisolvens, Bacteroides eggerthii, Lachnospira eligens, Akkermansia muciniphila, Ruminococcus lactaris, etc.) (p 0.05). The metabolic profile of the gut microbiome was characterized by increased metabolic processes aimed at the growth and division of microbial cells. Iron is the main limiting factor for growth and reproduction. In addition, it is important to note the prevalence of glycolysis and lactate fermentation as the major means for energy production by intestinal microbiota